Clinical Trial Update: IUdR/BUdR Cell Cycle Labelling [NA]

View source ↗

Summary

The study by MD Anderson Cancer Center evaluating IUdR and BUdR cell cycle labeling in hematologic malignancies has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• BUdR (bromodeoxyuridine)
• IUdR (iododeoxyuridine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hematologic Malignancies | NA | Status: COMPLETED